CTS will implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.
Read all about it on the Communication page by clicking this link: Communications
CTS lab staff recently participated in a Kaizen and determined emailed Daily Shipment Schedules to b...
The revised CTS algorithm associated with the Ortho platform is now available for review. Clie...
Dr. Buff Mair is the new CTS Medical Director and replaces Dr. German Leparc who retired at the begi...
As a friendly reminder, airlines often change their routine flights and cargo hours for holidays. We...
As a service to our partners, CTS provides a copy of all licenses and accreditations on our website....
On Wednesday August 15, 2018 at 11:00AM PDT, we will be hosting a webinar regarding the changes to F...